Clinical Trial Update: Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial studied the combination of docetaxel and flavopiridol in patients with refractory metastatic pancreatic cancer; the study is completed and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Flavopiridol (alvocidib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-01-10